Analysts Offer Predictions for CRSP Q1 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of CRISPR Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst M. Foroohar expects that the company will earn ($1.33) per share for the quarter. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.30) EPS, Q3 2025 earnings at ($1.26) EPS, Q4 2025 earnings at ($1.26) EPS and FY2026 earnings at ($5.17) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%.

Other analysts also recently issued research reports about the stock. Royal Bank of Canada dropped their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday. Needham & Company LLC reissued a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday. Barclays raised their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Finally, Truist Financial raised their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $74.05.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $43.49 on Thursday. The firm has a market cap of $3.71 billion, a P/E ratio of -15.37 and a beta of 1.67. CRISPR Therapeutics has a 1-year low of $36.52 and a 1-year high of $91.10. The firm’s 50-day simple moving average is $42.06 and its 200-day simple moving average is $46.25.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Highline Wealth Partners LLC purchased a new position in CRISPR Therapeutics in the 4th quarter worth about $39,000. Western Pacific Wealth Management LP increased its stake in CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics in the 3rd quarter worth about $40,000. Darwin Wealth Management LLC purchased a new position in CRISPR Therapeutics in the 3rd quarter worth about $43,000. Finally, Eastern Bank purchased a new position in CRISPR Therapeutics in the 3rd quarter worth about $70,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.